title: p38 kinase inhibitors for the treatment of arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureas.
abstract: Inhibitors of the MAP kinase p38 are potentially useful for the treatment for osteoporosis, arthritis, and other inflammatory diseases. A series of thienyl, furyl, and pyrrolyl ureas has been identified as potent p38 inhibitors, displaying in vitro activity in the nanomolar range.
authors.affiliation: Department of Chemistry Research, Bayer Research Center, Pharmaceutical Division, West Haven, CT 06516, USA. aniko.redman.b@bayer.com
authors.forename: A M
authors.initials: AM
authors.lastname: Redman
authors.forename: J S
authors.initials: JS
authors.lastname: Johnson
authors.forename: R
authors.initials: R
authors.lastname: Dally
authors.forename: S
authors.initials: S
authors.lastname: Swartz
authors.forename: H
authors.initials: H
authors.lastname: Wild
authors.forename: H
authors.initials: H
authors.lastname: Paulsen
authors.forename: Y
authors.initials: Y
authors.lastname: Caringal
authors.forename: D
authors.initials: D
authors.lastname: Gunn
authors.forename: J
authors.initials: J
authors.lastname: Renick
authors.forename: M
authors.initials: M
authors.lastname: Osterhout
authors.forename: J
authors.initials: J
authors.lastname: Kingery-Wood
authors.forename: R A
authors.initials: RA
authors.lastname: Smith
authors.forename: W
authors.initials: W
authors.lastname: Lee
authors.forename: J
authors.initials: J
authors.lastname: Dumas
authors.forename: S M
authors.initials: SM
authors.lastname: Wilhelm
authors.forename: T J
authors.initials: TJ
authors.lastname: Housley
authors.forename: A
authors.initials: A
authors.lastname: Bhargava
authors.forename: G E
authors.initials: GE
authors.lastname: Ranges
authors.forename: A
authors.initials: A
authors.lastname: Shrikhande
authors.forename: D
authors.initials: D
authors.lastname: Young
authors.forename: M
authors.initials: M
authors.lastname: Bombara
authors.forename: W J
authors.initials: WJ
authors.lastname: Scott
mesh_terms: D001168:Arthritis / Q000188:drug therapy*; D004791:Enzyme Inhibitors / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use*; D005663:Furans / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D020128:Inhibitory Concentration 50; D015850:Interleukin-6 / Q000378:metabolism; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors*; D015394:Molecular Structure; D010024:Osteoporosis / Q000188:drug therapy*; D011758:Pyrroles / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D013876:Thiophenes / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D014407:Tumor Cells, Cultured; D014508:Urea / Q000031:analogs & derivatives*; D048051:p38 Mitogen-Activated Protein Kinases; D000093242:Interleukin-6 Inhibitors
chemical_list: D004791:Enzyme Inhibitors; D005663:Furans; D015850:Interleukin-6; D020928:Mitogen-Activated Protein Kinases; D011758:Pyrroles; D013876:Thiophenes; D014508:Urea; D048051:p38 Mitogen-Activated Protein Kinases; D000093242:Interleukin-6 Inhibitors